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Abstract
Purpose—Effective cancer treatment generally requires combination therapy. The combination
of external beam therapy (XRT) with radiopharmaceutical therapy (RPT) requires accurate 3-D
dose calculations to avoid toxicity and evaluate efficacy. We have developed and tested a
treatment planning methodology, using the patient-specific 3-dimensional dosimetry package 3D-
RD, for sequentially combined RPT/XRT therapy designed to limit toxicity to organs at risk.
Methods—The biological effective dose (BED) was used to translate voxelized RPT absorbed
dose (DRPT) values into a normalized total dose (or equivalent two-Gray-fraction XRT absorbed
dose), NTDRPT map. The BED was calculated numerically using an algorithmic approach, which
enabled a more accurate calculation of BED and NTDRPT. A treatment plan from the combined
Samarium-153 and external beam was designed which would deliver a tumoricidal dose while
delivering no more than 50 Gy of NTDsum to the spinal cord of a patient with a paraspinal tumor.
Results—The average voxel NTDRPT to tumor from RPT was 22.6 Gy (1-85 Gy range); the
maximum spinal cord voxel NTDRPT from RPT was 6.8 Gy. The combined therapy NTDsum to
tumor was 71.5 Gy (40-135 Gy range) for a maximum voxel spinal cord NTDsum equal to the
maximum tolerated dose of 50 Gy.
Conclusions—A methodology which enables real time treatment planning of combined RPT-
XRT has been developed. By implementing a more generalized conversion between the dose
values from the two modalities and an activity-based treatment of partial volume effects, the
reliability of combination therapy treatment planning has been expanded.
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I. INTRODUCTION
Effective cancer treatment generally requires combination therapy. Combined external beam
therapy (XRT) with radiopharmaceutical therapy (RPT) treatment for metastatic patients
presents a possible advantage by providing localized high absorbed dose to the region of
visible tumor, while at the same time enabling treatment of less-discernable distributed
tumor sites. This treatment combination requires accurate 3-D dose calculations to avoid
toxicity and evaluate efficacy. Using patient data from a phase I/II trial and the dosimetry
software package, 3D-RD, we have developed and tested a methodology for sequentially
combined RPT/XRT treatment planning focused on limiting toxicity to organs at risk.
The starting point for integrating RPT and XRT is recognizing that RPT and XRT absorbed
doses are not Gray-for-Gray equivalent and can be expected to have different biological
effects due to differing dose rates; each fraction of the XRT delivered dose being essentially
instantaneous with multiple fractions being delivered over time, and the RPT dose delivered
over an extended period of time as the activity distributes and decays. Using the biological
effective dose (BED) formalism (1,2), the RPT absorbed dose (DRPT) can be converted to
BED and then to XRT two-Gray-fraction-equivalent absorbed dose (NTDRPT, where the
RPT in the subscript indicates the origin of the dose, as opposed to DXRT, absorbed dose
from XRT; and NTD stands for normalized total dose, the conventional appellation of two-
Gray-fractionated absorbed dose).
Previous studies (3,4) have shown how absorbed doses from these two treatment modalities
may be combined by converting absorbed dose values to BED values. The methodology
presented here is based on this prior formalism, but has been extended to allow for a wider
variability in pharmacokinetic input (i.e., dose-rate kinetics are not limited to a decreasing
monoexponential function (5)) and for the conversion of results into an absorbed dose map
that is radiobiologically consistent with that obtained from external beam. In radionuclide
imaging, inherent limitations on the resolution of imaging devices lead to a smoothing of the
true spatial activity distribution. In concentrated, high activity areas, this leads to a “spill-
out” (or partial volume (PVE)) effect in which regions adjacent to the high activity region
appear to have activity concentrations that exceed the true concentration. These effects are
then propagated to the absorbed dose distribution, via the Monte Carlo simulation. Therefore
an activity-based correction on the activity distribution is implemented (6,7).
Treatment planning for external beam radiotherapy has a long and well-established history.
In comparison, such methodologies have only recently been introduced for radionuclide
therapy (8,9). This study describes a first step towards an integrated treatment planning
approach combining these two therapeutic modalities.
II. METHODS
153Samarium
The active agent used in this study, Samarium-153 ethylenediaminetetramethylene
phosphonic acid (153Sm-EDTMP) is a bone-seeking radiopharmaceutical designed to
selectively deliver radiation to osteoblastic skeletal metastases (10). The radioisotope 153Sm
emits an electron (β− particle) with an average energy of 224 keV (approximate range of 0.5
mm), which is appropriate for targeted cytotoxicity. It has a half-life of 46.3 hours and its
photon emissions include a 103 keV photon with 28.3% abundance, which was used for
quantitative imaging. The use of 153Sm-EDTMP for palliative treatment of bone metastases
from a variety of carcinomas is well established and its therapeutic value for patients with
osteosarcoma is being investigated (11,12).
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Procedure
The 3D-RD combination of RPT and XRT treatment planning is a multi-step process. The
individual steps are described in detail below.
1. Data Acquisition—After administration of 16.7 GBq of 153Sm, SPECT/CT images
from two different time points (4h, 48h) were acquired. The SPECT images were
reconstructed using the QSPECT method developed by He et al. (13), based on the iterative
ordered-subsets expectation-maximization algorithm (30 iterations, 16 subsets per iteration)
(14) with reconstruction-based compensation for attenuation, scatter, and the collimator-
detector response function (CDRF). The attenuation was modeled using measured CT-
based attenuation maps. Scatter compensation was performed using a fast implementation of
the effective source scatter estimation method (15). Point sources at various distances from
the face of the collimator were simulated to estimate the distance-dependent CDRF that
included interactions and penetration of photons in the collimator and detector.
Camera saturation was accounted for by applying an exponential response function instead
of a linear sensitivity value to the counts in each projection image:
(1)
The exact values for the response were obtained by imaging a flat phantom (16) used in the
context of 2-dimensional imaging (a = 43060 cps/GBq, b = 0.715 GBq-1, R2 value > 0.99).
2. Co-registration—The reconstructed SPECT images were registered to each other
across time by registering the CT portion of the SPECT/CT images on a HERMES
(HERMES Medical Solutions; Stockholm, Sweden) workstation. The images were then
loaded into the 3D-RD software (6,17).
3. VOI determination—A co-registered CT image was loaded into the XRT treatment
planning software, Philips Pinnacle3 Radiation Treatment Planning System (Koninklijke
Philips Electronics; Eindhoven, Netherlands), where contours for the tumor VOI and the
radiation sensitive dose limiting VOI, in this case the spinal column, were drawn by the
radiation oncologist. A baseline intensity modulated radiation therapy (IMRT) treatment
plan was also designed based on delivering a dose of 30 Gy to 90% of the tumor voxels,
while minimizing the dose to the spinal column.
4. Spill-out (PVE) correction—The SPECT co-registered activity images and a co-
registered CT image were imported into the 3D-RD software package and the VOI map was
imported from Pinnacle. Clinical cases where target VOIs, generally tumors, and sensitive
VOIs (in our case, the spinal cord) exist in close proximity to each other present a particular
problem: the dose estimation can be skewed in sensitive regions due to high measured
activity artificially created in the SPECT or PET emission images due to spill-out (PVE),
miss-registration, and/or miss-identification of sensitive VOIs (3,4). To first order, it can be
assumed that all activity in excess of the background amount in the sensitive VOI is due to
spill-out. Using an approach described earlier (6,7), the activity in the spinal column voxels
which are proximal to the tumor VOI are replaced with the background activity values taken
from areas of the spinal column VOI not immediately adjacent to regions of high uptake.
5. 3D-RD Monte Carlo—A more complete description of 3D-RD has been given in detail
elsewhere (6,17,18), briefly: using Electron Gamma Shower (EGS) Monte Carlo (MC)
software, ten million events were run for the β- and photon components of the 153Sm decay
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spectra based on the SPECT images for each time point. The energy deposition distribution
from the contributing components from MC were weighted for probability and activity and
converted to absorbed dose rate for the VOIs (spectra probability distributions obtained from
LBL/Lund web site (19)).
6. RPT absorbed dose calculations (DRPT)—Using the dose rates calculated from the
Monte Carlo output at the two time points, a functional fit was made for the VOIs as a whole
and for the individual voxels. A monoexponential fit of the form:
(2)
was considered and the effective decay constant, λ, was calculated for each fit. If the decay
constant was physical (λ > λφ, where λφ is the decay constant for 153Sm equal to 0.01498
h-1) the fit consisted of a linear fit between the origin and the first time point, followed by
the monoexponential decay (see figure 1). If the decay constant was non-physical, a line was
drawn between the two time points and an exponential tail with the 153Sm physical decay
constant, λφ, was implemented after the second time point. The resulting area under the
curve was calculated as absorbed dose. The calculation was performed both on a voxel level,
thereby accounting for density and kinetic differences amongst voxels, and also on a whole
VOI level.
7. Absorbed dose conversion: NTDRPT—The formula for the BED using RPT is
(1,2):
(3)
Where α and β are the respective linear and quadratic radiosensitivity coefficients in the
linear quadratic equation (20), and G(T) is the Lea-Catcheside G-factor (21,22). The G-
factor is a function of another radiobiological parameter, μ, the DNA repair rate, assumed
exponential. The generalized expression of the G-factor is:
(4)
For a monoexponential fit to the dose rates, this factor reduces to the formula:
(5)
A period of uptake is expected for most organs and tumors, resulting in kinetics curves that
are not well-modeled by monoexponential decay. On a voxel basis the kinetics rarely satisfy
a mono- or double exponential relationship. In these case, the BED is most easily obtained
by numerical integration (5).
The values used for the radiobiological parameters were α/β = 5.4 Gy and μ = 1.73 Gy-1 for
osteosarcoma (23), and α/β = 3.33 Gy (24) and μ = 0.46 Gy-1 for the spinal cord (3).
The BED formula for XRT is:
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(6)
where N is the number of fractions of dose d, in Gray, with DXRT = Nd. By combining
Equations (3) and (6), a conversion formula for DRPT to  is derived, where , is
the absorbed dose from RPT in values consistent with XRT delivered in d Gray fractions:
(7)
For different treatments, different d values are used; a value of d = 2 Gy for therapy is not
uncommon and was the value used in this paper; consequently, the notation used will
henceforth be NTDRPT, where NTD stands for normalized standard dose.
8. Combination treatment planning—The NTDRPT maps were imported into Pinnacle
and added to the pre-established (step 3) external treatment plan (NTDXRT) multiplied by a
factor, k, such that the highest total voxel absorbed dose NTDsum in the sensitive region is
equal to the maximum tolerated dose (MTD) for that organ, in the present case equal to 50
Gy for the spinal cord. The mathematical formulation of this process is given by:
(8)
where for each voxel indexed by i, the scale factor ki is calculated which delivers the MTD,
given a baseline NTDXRT value from XRT of (NTDXRT)i and a NTDRPT value from RPT
of (NTDRPT)i The smallest of all ki values is taken as the definitive scale factor, k.
Note that this specific formulation is necessary for serial organs such as the spinal column,
where the MTD limit is placed on each voxel. For parallel organs at risk, a single value k for
the entire organ may be substituted. Second, should the MTD constraint be placed on BED
rather than NTDXRT, a simple conversion (Eq. 6) can be applied to the MTD to convert the
value to an NTDXRT equivalent MTD.
Finally, the total absorbed dose for each voxel is given by:
(9)
where the NTDRPT component has already been delivered and NTDXRT is the original
baseline external beam absorbed dose component (from step 3). The total absorbed dose that
will be delivered by external beam in this scenario is k NTDXRT.
Clinical Case
The patient was a 21-year-old male with a four year history of osteogenic sarcoma. After
multiple rounds of chemotherapy and surgery, including resection of two vertebrae, the
patient was enrolled in a phase I trial of 153Samarium (44.4 MBq/kg) in high risk osteogenic
sarcoma (25), as well as in a high dose (222 MBq/kg) 153Samarium protocol with peripheral
blood stem cell support. Subsequently, the patient was considered for additional external
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beam radiotherapy, at which point the issue of potential toxicity to the spinal column from
combined treatment was raised. However the patient elected palliative care closer to home
and the XRT was not administered.
III. RESULTS
RPT absorbed dose calculations
Figure 1 shows the dose rate kinetics curve from 153Sm RPT for the tumor VOI considered
as a single unit. The corresponding absorbed dose, DRPT, to the tumor VOI is 29.6 Gy. The
voxel-averaged absorbed dose, (DRPT), is 29.2 Gy, the small difference reflecting the impact
of density and kinetic variations within the tumor VOI. The spinal cord is not considered as
a single unit since the toxicity is based on the highest dose to a single voxel. The voxel-
averaged absorbed dose, (DRPT), to the spinal cord is 5.8 Gy. Applying Equation (7) to the
voxelized results gave average voxel normalized total doses, (NTDRPT), from RPT, of 22.6
Gy and 3.9 Gy for the tumor and spinal column, respectively, with a maximum spinal cord
voxel dose of 6.8 Gy. These results are illustrated in the form of cumulated dose volume
histograms (DVHs) in Figure 2.
Combined treatment planning
The voxelized NTDRPT results are combined with the absorbed doses from the IMRT
treatment plan, kNTDXRT scaled to deliver a maximum of 50 Gy combined NTDsum to the
spinal cord by using Equation (8). Figure 3a shows the cumulated DVHs for the baseline
IMRT treatment plan, while figure 3b shows the cumulated DVHs for the combined RPT
plus scaled IMRT treatment plan. The value calculated for the k-factor for the combined
plan was 1.64. Applying this factor to the baseline XRT plan and summing the two dose
distributions resulted in average voxel (NTDsum) values of 71.5 Gy and 20.6 Gy for the
tumor and spinal column, respectively. Figure 4 shows the NTDsum isodose contours as well
as the VOIs as defined in Pinnacle and used in the 3D-RD calculation.
IV. DISCUSSION
Sequence of treatments
In this case example, RPT has already been administered and dosimetry to scale the XRT
plan is needed to limit the combined treatment toxicity. Other scenarios may be envisioned
where the order is reversed, XRT having been implemented and an imaging/dosimetry tracer
study of the radiopharmaceutical would be performed to determine the activity level for the
RPT. In either scenario, for a clinical implementation, the methodology should include use
of a fixation device or mold that would insure reproducible positioning of the patient and all
images should be registered to the CT associated with the second treatment (i.e., either XRT
or SPECT/CT for RPT).
The time frame for the sequence of treatments was intended to be 2-3 weeks between RPT
and XRT, where the assumption is that of a worst case scenario where no long-term gross
tissue repair to normal organs takes place in the time between treatment modalities. For
longer intervals, this assumption may not be reasonable and a combined therapy model
which incorporates gross tissue repair may be considered as preferable. Note also that the
formula used for the BED and dose conversion does not account for proliferation and
assumes that the RPT radiation is effective through complete decay. Revisions to the BED
formulation that account for proliferation have been published (26,27) and could be used as
an alternative, although the spatial distribution of cell proliferation (i.e: at the voxel level) is
unlikely to be uniform and this would not to be taken into account.
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Activity spill-out
As figure 4 shows, the entire vertebral body was considered to be diseased; consequently a
large interface between tumor VOI and sensitive VOI is present along with a very high
potential for toxicity, both real and artificially perceived from activity spill-out. The
estimation of absorbed dose to the spinal cord depends on the method of dealing with spill-
out activity from the tumor region. Figure 5 shows the cumulated DVH for the tumor and
spinal cord calculated in 3D-RD if no activity corrections are made, which results in
NTDRPT values that are close to the MTD in the spinal cord and if taken at face value would
severely limit the amount of XRT available to the patient. However, not all of the dose to the
spinal VOI can be attributed to erroneously located activity; consequently a simple cut on
dose, i.e. eliminating the dose in the sensitive VOI, can seriously underestimate the amount
of absorbed dose to the spinal column. Applying a correction at the level of activity rather
than absorbed dose makes it possible to account for the dose to the sensitive volume arising
from adjacent tumor activity (and spinal cord background activity).
For this particular isotope with a relatively low energy β particle and very low photon
energy, the elimination of artificial spill-out activity within spinal cord resulted in a
relatively low absorbed dose (< 8 Gy); for other isotopes this value could potentially
increase quite considerably.
Superior methods of redistribution of activity from PVE are available (28), which relocate
the spill-out activity to their source. However, such methods are not universal and their
practical application carry other constraints such as an assumed homogeneity of tumor
activity (clearly not the case for osteosarcoma (25)), or simple geometries of the tumor VOI
(not the case here either).
Patient safety issues and potential adjustments
Because of the importance of limiting toxicity and the uncertainty associated with the
radiobiological α/β value, a lower value for the spinal column (α/β= 2 Gy) is often used in
XRT and could be considered here for combined therapy.
Similarly, the use of the average value of the non-proximal spinal column activity as a
substitute for regions contaminated by spill-out could be altered to allow for greater local
variability and thus create a larger safety margin. Alternate values could be: (a) the average
background value plus the RMS value, or (b) an activity value in all voxels equal to the
maximum voxel value in the sensitive volume not proximal to the tumor. In the present
example, scenario (a) would results in an increase of 37% in the proximal activity, with a
maximum voxel NTDRPT of 5.0 Gy (127% of original method value), a k-factor of 1.60
(97.6%), and an average tumor (NTDsum) of 70.3 Gy (98.3%). For the second option those
values became: an increase of 109% in spinal activity, a maximum voxel NTDRPT of 7.0 Gy
(178% of original method value), a k-factor of 1.52 (92.9%), and an average tumor
(NTDsum) of 68.0 Gy (95.1%). In those cases in which the activity concentration in a
particular normal organ differs from one part to another, when there is no evidence of
disease, care should be taken in implementing this methodology;a possible approach would
be to use scenario (b).
Voxel resolution
The figures shown in this paper (Figure 4) are not of superior resolution and visual quality.
The CT image portion of the SPECT/CT is often acquired at a greater resolution (512×512
matrix) as opposed to the emission images (generally 128×128). Superimposing absorbed
dose results on high resolution CT mages can create a false sense of the accuracy and
resolution of the RPT data (and most often of the IMRT treatment plan) which can only be
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calculated at the emission data resolution with any pretense at accuracy. Even at this low
resolution (4.4 mm per voxel side), uncertainties at the voxel level are important – from
attenuation, scatter, patient motion, registration, and spill-out. It has been noted that for
objects of size or distances between VOIs smaller than the SPECT resolution (6,7), more
accurate dosimetry may be obtained by modeling the uptake and energy deposition. Clearly
this is the necessary direction for future combined treatment planning.
Anatomically, the spinal cord is surrounded by cerebrospinal fluid (CSF), which provides a
cushion of protection. This CSF barrier is not present in the treatment plan (Figure 4), yet
would be the anatomical feature closest to the tumor and diseased vertebra and consequently
receive the most dose from tumor activity. Possibly, the spinal column receives less
absorbed dose than calculated in this study, and the effects of the CSF would best be
understood through modeling. However, because of the disease outgrowth, assuming a
standard depth of CSF between vertebra and spinal cord may also be erroneous, as the
disease impinges upon the column, reducing the CSF buffer significantly.
IMRT treatment comparison
For comparison, a simple IMRT treatment plan was calculated by scaling the baseline plan
shown in Figure 3a to the spinal column MTD. The voxel-averaged absorbed dose values to
the tumor and spinal column were 54.6 Gy and 18.6 Gy, respectively. These compare to
71.5 and 20.6 Gy for the combined plan (Fig 3b). The approximate 17-Gy increase in tumor
absorbed dose obtained by combining RPT with XRT belies the relative contribution of RPT
in a combined RPT/XRT treatment. Specifically, in XRT optimization methods, the tumor
volume as drawn on CT (with some margin added) is traditionally used. This approach
makes it difficult to consider the contribution of RPT in a combined treatment plan, since, in
addition to targeting the measurable tumor, RPT is also treating systemic or sub-detectable
disease that is not accounted for in the DVH, while simultaneously including healthy tissue
not targeted by RPT, as in this particular instance where the whole vertebral body was
designated as tumor, which lowers the apparent average dose to the VOI from RPT.
BED and dGF
Throughout the course of this study a value of d = 2 Gy for fractionated therapy was chosen.
An equivalent procedure can be followed for any chosen d value. For example, a value of d
= 3 Gy would result in average voxel 3-Gray-equivalent absorbed doses, ,of 19.9 Gy
and 3.3 Gy for the tumor and spinal column, respectively, with a maximum spinal cord
voxel dose of 5.7 Gy. The k-factor would have been 1.67 to deliver no more than the MTD
of 50 Gy to the spinal cord. However, 50 Gy of 3-Gy fractionation is not biologically
equivalent to 50 Gy of 2-Gy fractionated radiotherapy, and there would be a greater risk of
toxicity to the spinal column in this case.
More than a bridge between different absorbed dose systems, the BED is the quantity that
reflects the biological effects of the dose and is thus the absolute reference (29); any MTD in
radiotherapy ultimately should be defined in BED and the necessary conversions made to
and from that quantity. The BED – equivalent spinal column MTD for a 50 Gy NTD MTD
would be 80.0 Gy and is only 42.1 Gy of D3GF. Applying 50 Gy of D3GF would be
biologically equivalent to 59.4 Gy for the spinal cord of NTD and represents a BED of 95.0
Gy.
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V. CONCLUSIONS
Important additions to the practical application of combined RPT-XRT treatment have been
implemented within the framework of 3D-RD, potentially enabling effective sequential
combination therapy.
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Figure 1.
dose rate plots for the tumor VOI. The blue triangles show the calculated dose rates and the
blue lines represent the fit used to calculate the DRPT. The red dotted line shows the
monoexponential fit. The resulting DRPT, BED, and NTDRPT values are also shown.
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Figure 2.
cumulated dose volume histograms for the NTDRPT values in the tumor and spinal cord
calculated in 3D-RD from 153Sm.
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Figure 3.
cumulated dose volume histograms for the (a) baseline IMRT NTDXRT values, and (b) the
combined therapy NTDsum, in the tumor and spinal cord. In figure 3b, the blue dotted lines
show that 90% of the tumor VOI receives 55.3 Gy of combined dose.
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Figure 4.
Isodose contours in Pinnacle showing the combined therapy treatment plan. Pink is the
planning tumor volume (PTV) and the volume used in the 3D-RD calculation, blue is the
additional gross tumor volume (GTV), green is the contour identifying the spinal cord as the
sensitive volume, and yellow an artificial VOI used to confine the DXRT to the GTV, often
called a “ring”.
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Figure 5.
cumulated dose volume histograms for the NTDRPT values in the tumor and spinal cord
from a 3D-RD calculation with no activity spill-out correction.
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